MariTide and CT-388: Amgen and Roche Drugs Explained

Editorial correction: An earlier version of this article incorrectly identified MariTide as Roche’s CT-388. These are different investigational drugs. This correction is awaiting medical review.

Are MariTide and CT-388 the same drug?

No. MariTide is developed by Amgen; CT-388 is a separate drug developed by Roche. Their names, mechanisms and study results should not be used interchangeably.

This article distinguishes the two candidates using dated primary sources. It is for general information, not guidance on choosing or starting treatment.

What is Amgen’s MariTide?

MariTide is the name used for maridebart cafraglutide, formerly AMG 133. Amgen describes it as an investigational antibody–peptide conjugate that activates GLP-1 receptors and blocks GIP receptors. The GIP-blocking action is important: MariTide is not a dual GLP-1/GIP receptor agonist.

In its May 2026 overview, Amgen describes monthly or less frequent dosing under investigation and the Phase 3 MARITIME clinical program. A studied dosing schedule is not an approved prescribing schedule.

See the Amgen MariTide overview for the source behind this description.

What is Roche’s CT-388?

CT-388 is a separate investigational once-weekly injectable GLP-1/GIP dual receptor agonist. Unlike MariTide, it activates both receptors.

Roche also calls CT-388 enicepatide. In its September 22, 2026 update, Roche described ongoing Phase III ENITH-1 and ENITH-2 chronic-weight-management studies; the medicine remains investigational. Roche Phase III update.

Roche announced Phase II CT388-103 topline results on January 27, 2026. The trial enrolled 469 adults with obesity, or overweight with a weight-related condition, without type 2 diabetes. Roche reported weight-loss findings at 48 weeks; the announcement said full study results would be presented at a future medical meeting. These were company-reported topline findings at the time of that release.

The Roche Phase II announcement concerns CT-388, not MariTide.

How should readers interpret these updates?

The cited announcements describe investigational treatments. They do not establish that either drug is approved or available for routine prescribing. Development status can change, so check current regulator and trial records rather than assuming availability from a news report.

Results from separate studies cannot establish that one treatment is better than another. Differences in study participants, doses, duration and analysis methods matter. This article does not make a head-to-head efficacy comparison.

If you are considering treatment for weight management, discuss approved options, potential benefits and risks with your healthcare professional. Do not use investigational products based on promotional claims or an online article.

Sources

1. Amgen. May 2026. The Story of Maridebart Cafraglutide
2. Roche. January 27, 2026. Phase II CT-388 obesity trial results
3. Roche. September 22, 2026. Enicepatide (CT-388) Phase III program update